Emulate
Emulate, Inc.: A Boston-based biotech firm innovating with Organs-on-Chips technology for precision medicine and product testing.
Founded
2013Emulate, Inc.: A Boston-based biotech firm innovating with Organs-on-Chips technology for precision medicine and product testing.
Emulate develops Organ-on-a-Chip platforms, consumables, and organ-model BioKits that recreate human organ-level functions using living human cells in micro-engineered environments. Its Zoë-CM2 Culture Module instruments up to 12 Organ-Chips, while the AVA Emulation System scales to 96 chips per run for high-throughput studies.
The company offers ready-to-culture BioKits such as the Brain-Chip R1, an iPSC-derived model of the human neurovascular unit developed with FUJIFILM Cellular Dynamics. Customers include pharmaceutical, biotech, academic, and government laboratories pursuing human-relevant drug discovery and safety testing.
The organ-on-a-chip and microphysiological systems market is expanding as regulators move away from animal testing, with the FDA Modernization Act enabling alternative methods and the FDA and NIH signaling animal studies will become the exception within three to five years. Emulate is positioned to capture demand from pharmaceutical developers seeking human-relevant preclinical safety data.
Continued FDA ISTAND qualification and growing adoption across large pharmaceutical R&D organizations underpin near-term growth. Competition from CN Bio, Mimetas, TissUse, and Dynamic42 constrains pricing and requires Emulate to sustain its regulatory and publication lead.
Emulate is the only Organ-Chip company accepted into the FDA's ISTAND Pilot Program for drug-induced liver injury evaluation, and its technology is the sole Organ-Chip cited in the FDA Roadmap to Reducing Animal Testing. This regulatory positioning gives it a first-mover advantage as the FDA and NIH prioritize human-based testing.
The platform spans more than 30 organ models across over 130 peer-reviewed publications, supporting a broad customer base of major pharmaceutical companies. Its integrated instruments, consumables, and validated BioKits reduce workflow variability and lower adoption barriers relative to competing organ-on-chip systems.